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Evaluating the potential economic and health impact of 
rotavirus vaccination in 63 middle-income countries not 
eligible for Gavi funding: a modelling study
Frédéric Debellut, Andrew Clark, Clint Pecenka, Jacqueline Tate, Ranju Baral, Colin Sanderson, Umesh Parashar, Deborah Atherly
Summary
Background Middle-income countries (MICs) that are not eligible for funding from Gavi, the Vaccine Alliance, have 
been slow to adopt rotavirus vaccines. Few studies have evaluated the cost-effectiveness and benefit–risk of rotavirus 
vaccination in these settings. We aimed to assess the potential economic and health impact of rotavirus vaccination in 
63 MICs not eligible for funding from Gavi.
Methods In this modelling study, we estimated the cost-effectiveness and benefit–risk of rotavirus vaccination in 
63 MICs not eligible to Gavi funding. We used an Excel-based proportionate outcomes model with a finely 
disaggregated age structure to estimate the number of rotavirus gastroenteritis cases, clinic visits, hospitalisations, 
and deaths averted by vaccination in children younger than 5 years over a 10-year period. We calculated cost-
effectiveness ratios (costs per disability-adjusted life-years averted compared with no vaccination) and benefit–risk 
ratios (number of hospitalisations due to rotavirus gastroenteritis averted per excess hospitalisations due to 
intussusception). We evaluated three alternative vaccines available globally (Rotarix, Rotavac, and Rotasiil) and used 
information from vaccine manufacturers regarding anticipated vaccine prices. We ran deterministic and probabilistic 
uncertainty analyses.
Findings Over the period 2020–29, rotavirus vaccines could avert 77 million (95% uncertainty interval [UI] 51–103) 
cases of rotavirus gastroenteritis and 21 million (12–36) clinic visits, 3 million (1·4–5·6) hospitalisations, 
and 37 900 (25 900–55 900) deaths due to rotavirus gastroenteritis in 63 MICs not eligible for Gavi support. From a 
government perspective, rotavirus vaccination would be cost-effective in 48 (77%) of 62 MICs considered. The 
benefit–risk ratio for hospitalisations prevented versus those potentially caused by vaccination exceeded 250:1 in all 
countries.
Interpretation In most MICs not eligible for Gavi funding, rotavirus vaccination has high probability to be cost-
effective with a favourable benefit–risk profile. Policy makers should consider this new evidence when making or 
revisiting decisions on the use of rotavirus vaccines in their respective countries.
Funding Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Rotavirus infections were responsible for an estimated 
151 514 deaths in children younger than 5 years in 2019, 
along with millions of cases and hospitalisations.1 
Rotavirus vaccines have been available to low-income 
and middle-income countries since 2009, and they are 
cost-effective in most settings,2–5 a finding supported by a 
2019 analysis of countries currently and previously 
supported by Gavi, the Vaccine Alliance.6
As of July, 2020, more than 100 countries worldwide had 
introduced rotavirus vaccines in their national immuni-
sation programmes.7 Compared with low-income countries 
benefiting from international support for vaccine purchase 
and introduction, adoption of new and underused vaccines 
has been slower in middle-income countries (MICs) that 
do not benefit from international support.8,9 As of July, 2020, 
of the 63 MICs that are not currently eligible for financial 
support from Gavi, only 30 include rotavirus vaccines in 
their national immunisation programme, with most using 
Rotarix (manufactured by GlaxoSmithKline, Rixensart, 
Belgium).7,10 Barriers to introducing new vaccines are 
numerous, with affordability being one of the main 
challenges reported by countries in the absence of 
negotiated prices or pooled procurement.
Another possible barrier for MICs has been the 
perception of the possible risk of intussusception, a rare 
but serious bowel disorder that can lead to gut perforation 
or even death in settings without access to timely 
treatment. A small elevated risk of intussusception has 
been associated with rotavirus vaccination in some 
countries, but not in others.11,12
Studies exploring the benefits and risks of rotavirus 
vaccines in MICs estimate that the number of rotavirus 
deaths prevented by vaccination would greatly exceed any 
Lancet Glob Health 2021; 
9: e942–56
Published Online 
April 20, 2021 
https://doi.org/10.1016/
S2214-109X(21)00167-4
See Comment page e885
Center for Vaccine Innovation 
and Access, PATH, Geneva, 
Switzerland (F Debellut MSc); 
Department of Health Services 
Research and Policy, London 
School of Hygiene & Tropical 
Medicine, London, UK 
(A Clark PhD, 
Prof C Sanderson PhD); Center 
for Vaccine Innovation and 
Access, PATH, Seattle, WA, USA 
(C Pecenka PhD, R Baral PhD, 
D Atherly PhD); Division of Viral 
Diseases, US Centers for Disease 
Control and Prevention, 
Atlanta, GA, USA (J Tate PhD, 
U Parashar MD)
Correspondence to: 
Frédéric Debellut, Center for 
Vaccine Innovation and Access, 
PATH, 1202 Geneva, Switzerland 
fdebellut@path.org
Articles
e943 www.thelancet.com/lancetgh   Vol 9   July 2021
potential deaths caused by intussusception, and WHO 
maintains its recommendation that all countries 
introduce rotavirus vaccines in routine immunisation 
because of their substantial public health benefit.13 
However, due to continued concerns about rotavirus 
vaccine-associated intussusception in MICs, and because 
mortality from both rotavirus and intussusception is rare 
in those settings,14,15 providing benefit–risk ratios for 
hospitalisations (ie, the number of hospitalisations 
due to rotavirus prevented for every potential excess 
hospitalisation due to intus susception) could be useful 
for decision making.
Another important consideration for MICs is the 
availability of new rotavirus vaccines. For almost a 
decade, only two rotavirus vaccines, Rotarix and RotaTeq 
(manufactured by Merck, Kenilworth, NJ, USA), were 
available. In 2018, WHO prequalified two additional 
rotavirus vaccines: Rotavac (manufactured by Bharat 
Biotech, Hyderabad, India) and Rotasiil (manufactured 
by Serum Institute, Pune, India), both available at lower 
prices.16
Aiming to inform global and country policy makers, 
this study explores the cost-effectiveness and benefit–
risk of three WHO-prequalified and globally available 
rotavirus vaccines (Rotarix, Rotavac, and Rotasiil) in 
63 MICs that are not eligible for funding from Gavi. 
Although some MICs are already using rotavirus 
vaccines, many continue to face highly constrained 
budgets. An updated under standing of the cost-
effectiveness of currently available products can help 
countries assess their previous choices and make 




For this modelling study, we estimated the cost-
effectiveness and benefit–risk of rotavirus vaccination 
from government and societal perspectives in 63 MICs 
that are not eligible for funding from Gavi, over a 10-year 
period starting in 2020, using a comparator of no rotavirus 
vaccination. The study includes both countries already 
using rotavirus vaccines at the time of this analysis (n=30) 
and those that have not yet introduced them (panel).
We modelled the number of rotavirus gastroenteritis 
(RVGE) cases, clinic visits, hospitalisations, and deaths 
that would occur in children younger than 5 years in the 
absence of rotavirus vaccination in each country. We 
modelled the same series of outputs for each country 
assuming they would include rotavirus vaccines in their 
national immunisation programmes beginning in 2020 
to generate the number of health outcomes averted by 
vaccination, health-care costs averted, and vaccination 
costs.
We used UNIVAC (version 1.4.09), an Excel-based, 
deterministic proportionate outcomes model that has 
been used extensively for country-specific and global 
analyses.6,14,17–21
Rotavirus disease burden
We estimated the rate of non-severe RVGE cases, 
non-severe and severe RVGE clinic visits, severe RVGE 
cases, severe RVGE hospitalisations and RVGE deaths 
(appendix pp 2–3). We assumed that all non-severe cases 
were not fatal. Methods for estimating rotavirus disease 
burden have been described in detail elsewhere.6,14 The 
full list of country-specific data inputs and uncertainty 
Research in context
Evidence before this study
We searched PubMed for studies between Jan 1, 2008, 
and Feb 28, 2021, using the search terms “rotavirus vaccine”, 
“middle-income country”, “cost-effectiveness”, and “benefit-
risk”, with no language restrictions. We identified four global 
systematic reviews on the cost-effectiveness of rotavirus 
vaccination and one global systematic review on benefit–risk 
analyses. In middle-income countries that are not eligible for 
support from Gavi, the Vaccine Alliance, we found 28 cost-
effectiveness studies; however, none evaluated two new 
products that were prequalified in 2018. In terms of benefit–risk 
analyses, we found a modelling study done in 14 countries in 
Latin America that estimated benefit–risk ratios for deaths and 
hospital admissions, assuming age-restricted vaccination. 
Another modelling study covered 135 low-income and middle-
income countries and estimated benefit–risk ratios for deaths 
with and without age restrictions, but did not estimate the 
benefit–risk of hospital admissions. Therefore, little up-to-date 
evidence exists examining the cost-effectiveness and benefit–risk 
of rotavirus vaccination in countries not eligible for Gavi funding.
Added value of this study
This study provides estimates of the economic and public 
health impact of three oral rotavirus vaccines available in the 
global market for 63 middle-income countries that are not 
eligible for funding from Gavi. We present comprehensive 
evidence for decision makers assessing or re-assessing their 
investment regarding rotavirus vaccination. The model used in 
this study is available to country teams wishing to scrutinise 
and improve study inputs, explore additional scenarios, and 
inform national decision making.
Implications of all the available evidence
We found a high probability that rotavirus vaccines represent a 
good investment for most middle-income countries not eligible 
for Gavi support, as newer products entering the market expand 
product choice and enhance market competition. The benefits of 
rotavirus vaccination are likely to greatly exceed the potential 
intussusception risk. Countries should consider this new evidence 
when making or revisiting decisions on the use of these vaccines.
See Online for appendix
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ranges used to model disease burden is available in the 
appendix (pp 2–5).
We distributed the number of disease events in children 
younger than 5 years into weeks of age, on the basis of 
data from more than 90 hospital datasets.22 To avoid 
overstating the potential benefits of rotavirus vaccination, 
we assumed that the rotavirus mortality rate would 
decrease in the absence of vaccination by assuming a 
trend consistent with the decreasing trend in overall 
under-5 mortality. We used disability-adjusted life-year 
(DALY) weights for moderate and severe diarrhoea 
reported by Salomon and colleagues23 as proxies for non-
severe and severe RVGE.
Vaccine coverage, coverage timeliness, and efficacy
We used country-specific coverage rates for the first, 
second, and third doses of diphtheria-tetanus-pertussis 
vaccine (DTP) as proxies for coverage of the first, second, 
and third doses of rotavirus vaccine.24 Rotarix only 
requires two doses; therefore, only coverage for the first 
and second doses of DTP were used for this vaccine. 
Data for coverage timeliness were taken from Clark 
and colleagues,14 based on methods used in a previous 
analysis.25 Following initial recommendations from 
WHO based on the need to avoid the peak age of naturally 
occurring intussusception, some countries implemented 
an age-restricted schedule for delivery of rotavirus 
vaccines (first dose before 15 weeks and last dose before 
32 weeks). However, more recent work has shown that 
the positive benefit–risk profile of rotavirus vaccines 
supports the use of schedules without age restrictions, 
and WHO has adapted its recom mendations.13 To further 
inform MICs on this topic, we undertook our analysis 
for schedules with and without age restrictions.
Vaccine efficacy input data are drawn from a 2019 
pooled analysis of all published randomised controlled 
trials on oral rotavirus vaccines efficacy, which stratified 
data by under-5 mortality and dose and extrapolated for 
each country.26 We assumed efficacy against non-severe 
RVGE was 0·85 times the efficacy against severe RVGE 
on the basis of a study by Rogawski and colleagues.27
Costs assumptions
We used country-specific estimates published in 2020 
of outpatient and inpatient diarrhoea costs as a proxy 
for RVGE,28 accounting for government (health-care 
costs to the government alone) and societal perspectives 
(encompassing health-care costs to the government, 
costs supported by households as they seek care for 
their sick child, and loss of productivity). Direct medical 
costs were used as a proxy for health-care costs 
supported by the government, while direct medical 
costs plus direct non-medical and indirect costs were 
used as a proxy of health-care costs from the societal 
perspective. We modelled the direct medical costs 
of intussusception because we were unable to locate 
data on intussusception treatment costs for our list 
of countries. Detailed calculations and country-specific 
cost estimates are available in the appendix (pp 6–10). 
Because of the limited information on health-care 
costs, we did an uncertainty analysis with a wide range 
of –50% to +50% of base input.
To understand potential vaccine prices in settings 
where new vaccine products are not yet widely used, we 
asked respective manufacturers to provide an illustrative 
price or price range that might be available to the list of 
63 MICs. Merck has reported an inability to continue 
supplying rotavirus vaccines to countries in west Africa 
due to supply constraints. Additionally, the company has 
received new approval to sell vaccines in other markets at 
prices that far exceed those examined in this analysis. 
Therefore, RotaTeq was excluded from this study 
due to uncertainties about product availability at prices 
comparable with those we used.29 Although vaccine 
prices and ranges have been informed by industry and 
are consistent with prices reported by UNICEF,30 the 
prices used in this analysis should not be interpreted as 












Algeria, Botswana*, Equatorial Guinea, Gabon, Mauritius*, 
Namibia*, South Africa*
Americas region
Argentina*, Belize, Brazil*, Colombia*, Costa Rica*, 
Dominican Republic*, Ecuador*, Grenada, Jamaica, Mexico*, 
Panama*, Paraguay*, Peru*, Saint Lucia, Saint Vincent and 
the Grenadines, Suriname, Venezuela*
Eastern Mediterranean region
Iran, Iraq*, Lebanon, Libya*
Europe region
Albania*, Belarus, Bosnia and Herzegovina, Bulgaria*, Croatia, 
Kazakhstan, Kosovo, Montenegro, Romania, Russia, Serbia, 




China, Fiji*, Malaysia, Samoa, Tonga, Tuvalu
*Countries using rotavirus vaccine as part of their national immunisation programme 
as of July 9, 2020.7,10
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the prices that might be offered by any manufacturer to 
any single country. Rather, they are reflective of the 
ranges that might be available to MICs given varying 
prices by country. When making comparisons between 
products, countries are strongly encouraged to confirm 
the vaccine prices that will be available for their specific 
context. All vaccine parameters used in the study, 
along with details on how price and price ranges were 
calculated, are presented in the appendix (p 11).
The incremental cost of delivery represents all 
additional costs required to deliver vaccines other than 
the direct cost of vaccine procurement and commodities 
(eg, costs related to personnel, vaccine distribution, 
and storage). We searched the immunisation delivery 
cost catalogue for incremental economic delivery costs 
of vaccines for infants in lower-MICs and upper-
MICs.31 The search returned eight datapoints from four 
countries spanning four WHO regions. Because of this 
scarce evidence, we used the average value across the 
eight datapoints and explored uncertainty with a wide 
range of inputs (appendix p 11).
Cost-effectiveness
Our main outcome was the incremental cost-
effectiveness ratio (ICER), expressed in US dollars per 
DALY averted. We used 0·5 times the per capita gross 
domestic product (GDP) of each country as a threshold 
for cost-effectiveness, following the studies by Woods 
and colleagues32 and Ochalek and colleagues.33 We used 
a 3% discount rate on future costs and DALYs when 
calculating the cost per DALY averted.34–36 All costs in 
the analysis are reported in 2018 US dollars. Country-
specific undiscounted vaccination programme costs, 
undiscounted health-care costs averted, and number of 
fully immunised children were extracted to calculate the 
net cost of rotavirus vaccination and the net cost per 
fully immunised child in each country.
Intussusception and benefit–risk
To account for the potential risk of intussusception after 
rotavirus vaccination, we calculated benefit–risk ratios 
for each country, defined as the number of hospital 
admissions due to rotavirus averted per excess hospital 
admission due to intussusception. Methods used to 
calculate the number of excess intussusception cases are 
described in detail elsewhere.14 The relative risk (RR) 
of intussusception in the periods following the first 
(days 1–7) and second (days 8–21) doses was taken from a 
pooled meta-analysis of studies using the self-controlled 
case series method.14 Estimates of the incidence of 
intussusception in children younger than 5 years and the 
age distribution of intussusception by week of age under 
5 years were taken from a 2019 global review.37 In the 
absence of health-care utilisation data for intussusception, 
we assumed that the proportion of intussusception cases 
with access to a hospital would be the same as first DTP 
dose coverage in the country concerned, and we assumed 
that all cases without access to care would be fatal.
Uncertainty analysis
We did a deterministic analysis with our base-case values 
and a probabilistic analysis with 1000 runs per country. 
Averted rotavirus burden, thousands Averted health-care costs,* US$ thousands
Cases Visits Hospitalisations Deaths DALYs* Government 
perspective
Societal perspective
All 63 MICs 76 797·5 
(51 118·2 to 102 829·4)
20 996·0 
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Averted rotavirus burden, thousands Averted health-care costs,* US$ thousands
Cases Visits Hospitalisations Deaths DALYs* Government 
perspective
Societal perspective
(Continued from previous page)
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Eastern Mediterranean 
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12 917 
(6539 to 23 279)
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Averted rotavirus burden, thousands Averted health-care costs,* US$ thousands
Cases Visits Hospitalisations Deaths DALYs* Government 
perspective
Societal perspective
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6055·3 
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Parameters included in the probabilistic analysis and 
the statistical distributions used are presented in the 
appendix (pp 12–13). We built a cost-effectiveness 
acceptability curve for each vaccine and report the 
probability that vaccination would be cost-effective at 
different possible thresholds, including our main 
reported threshold of 0·5 GDP per capita.
The model assumed equal dose-specific efficacy and 
duration of protection associated with each dose, 
irrespective of the product used. Therefore, vaccines 
with three doses were predicted to have slightly higher 
impact than products with two doses. As this has not 
been shown empirically, it should not be over-
interpreted. Our estimates of vaccine impact reflect that 
of the three-dose vaccines (Rotavac and Rotasiil). 
Equivalent estimates for the two-dose Rotarix vaccine are 
shown in the appendix (pp 14–15, 18–19, 28–30). We also 
did the analysis assuming Rotarix would provide an 
impact equivalent to that of the three-dose vaccines 
(appendix pp 24–27).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
We present here the vaccine impact and cost-effectiveness 
results for age-restricted schedules. Equivalent results for 
age-unrestricted schedules are shown in the appendix 
(pp 16–19, 22–23). Over the period 2020–29, we estimated 
that the use of rotavirus vaccines in all MICs not 
eligible for funding from Gavi has the potential to avert 
77 million (95% uncertainty interval [UI] 51–103) cases of 
RVGE and 21 million (12–36) clinic visits, 3 million 
(1·4–5·6) hospitalisations, and 37 900 (25 900–55 900) 
deaths due to RVGE (table 1). These findings 
would amount to 1·2 million (0·8–1·7) DALYs averted. 
Discounted costs averted from clinic visits and 
hospitalisations would be US$826 million (370–1664) 
from a government perspective and $1182 million 
(535–2361) from a societal perspective (table 1). MICs not 
yet using rotavirus vaccines where a substantial disease 
burden could be averted by their introduction included 
Egypt, the Philippines, China, and Iran.
In all countries, vaccination costs were estimated to be 
systematically lower with Rotavac and Rotasiil than with 
Rotarix, with a slight cost advantage to Rotasiil (table 2). 
The estimated net cost per fully immunised child, 
accounting for the difference in undiscounted vaccination 
programme costs and undiscounted averted treatment 
costs, ranged from –$5 with Rotasiil in Lebanon to $33 with 
Rotarix in Venezuela (appendix pp 33–42).
We estimated that, from the government perspective, 
48 (77%) of 62 MICs (excluding Syria, as no GDP data 
was available at the time of this study) have a 
deterministic ICER lower than 0·5 times their GDP per 
capita with at least one of the rotavirus products 
under consideration (table 2). This includes 21 of the 
33 countries not yet using rotavirus vaccines. When 
evaluating from the societal perspective, the number of 
countries with an ICER lower than the threshold rose to 
54 (87%) of 62 countries. Deterministic ICERs from the 
government and societal perspectives and a comparison 
with the threshold are available in the appendix 
(pp 20–23).
Both Rotavac and Rotasiil were estimated to have a 
90% or higher probability of being cost-effective at 
the 0·5 GDP per capita threshold in 39 (Rotavac) 
and 41 (Rotasiil) countries (table 2). Rotarix has a 90% 
or higher chance of being cost-effective at the same 
threshold in nine countries. We estimated that, for 
17 countries not yet using rotavirus vaccines nationally, at 
least one product had a 90% or higher chance of being 
cost-effective at the 0·5 GDP per capita threshold. If 
these 17 countries were to use rotavirus vaccines, 
they would prevent 16 759 (95% UI 11 920–22 086) RVGE 
deaths over 10 years (appendix p 43).
Overall, we estimated Rotasiil to be the least costly and 
most cost-effective choice for all countries, followed 
closely by Rotavac. The cost-effectiveness acceptability 
curve for this dominant option (figure) highlights 
countries where rotavirus vaccination is less likely to 
be cost-effective at a 0·5 GDP per capita threshold. 
Countries in which the probability of rotavirus vaccines 
being cost-effective was lower than 50% (using 0·5 GDP 
Averted rotavirus burden, thousands Averted health-care costs,* US$ thousands
Cases Visits Hospitalisations Deaths DALYs* Government 
perspective
Societal perspective





























Data are estimates (95% uncertainty interval) compared with no vaccination and assuming a three-dose, age-restricted schedule in all countries. DALYs=disability-adjusted life-years. MIC=middle-income 
country. *Discounted values at 3% per year. †Countries using rotavirus vaccine as part of their national immunisation programme as of July 9, 2020.7,10
Table 1: Vaccine impact results over the period 2020–29
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7361 0% 44% 58%
(Table 2 continues on next page)
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perspective*
Rotarix Rotavac Rotasiil Rotarix Rotavac Rotasiil Rotarix Rotavac Rotasiil
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6967 63% 98% 99%
(Table 2 continues on next page)
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per capita as the threshold) include two in the eastern 
Mediterranean region (Palestine and Jordan), five in 
the European region (Albania, Belarus, Bosnia and 
Herzegovina, Kosovo, and Serbia), and one in the western 
Pacific region (Tonga). Acceptability curves for Rotarix 
and Rotavac are available in the appendix (pp 31–32). 
Although Rotavac showed similar probabilities of being 
cost-effective to Rotasiil, Rotarix probabilities were lower 
than both products.
With strict adherence to age restrictions, we estimated 
that rotavirus vaccines could prevent about 3 million 
RVGE hospital admissions across all 63 countries over a 
10-year period, increasing to 4·5 million without age 
restrictions (table 3). Over the same period, hospital 
admissions caused by excess cases of intussusception 
would be approximately 2900 with age restrictions or 
6700 without age restrictions. The benefit–risk ratio 
was approximately 1000:1 with age restrictions and 
670:1 without age restrictions. The incremental benefit–
risk among children who would receive the vaccine 
outside the recommended age windows was approxi-
mately 383:1 and was not lower than 262:1 in any of the 
countries assessed (table 3).
Discussion
Rotavirus vaccination has the potential to avert 
substantial disease burden and is likely to be cost-
effective in 77% of MICs not eligible for support from 
Gavi, on the basis of a willingness-to-pay threshold set 
at 0·5 times the national GDP per capita. Recently 
prequalified vaccines might provide good value for 
money if offered at the prices indicated by manufacturers. 
Rotasiil was estimated to be the most cost-effective 
product in all countries, followed closely by Rotavac. This 
pattern remains sensitive to assumptions about inputs, 
particularly costs of delivery and vaccine prices.38
An early rotavirus vaccine, RotaShield (Wyeth-Ayerst, 
Philadelphia, PA, USA), was withdrawn from the market 
in the USA after its association with one excess case of 
intussusception per fewer than 10 000 fully vaccinated 
individuals.39 However, evidence from self-controlled 
case-series studies in the past few years suggests that the 
current generation of rotavirus vaccines are associated 
with a much lower level of risk and, in some settings, no 
elevated risk. For example, studies of Rotarix and Rotavac 
in low-income settings have reported no elevated risk.40,41 
In MICs, where the potential risk of intussusception 






Probability for cost per DALY 
averted to be <0·5 GDP per 
capita, government 
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Rotarix Rotavac Rotasiil Rotarix Rotavac Rotasiil Rotarix Rotavac Rotasiil

















































































































































3124 1% 56% 66%
Data are estimates (95% uncertainty interval), unless otherwise specified. Estimates assume a three-dose age-restricted schedule in all countries. Each vaccine is compared with no vaccination. All data are in 
2018 US dollars. CS=cost saving. DALYs=disability-adjusted life-years. GDP=gross domestic product. NA=not applicable. *Countries using rotavirus vaccine as part of their national immunisation programme, as 
of July 9, 2020.7,10 †Values discounted at 3% per year.
Table 2: Cost-effectiveness results per country in the period 2020–29
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might have been an obstacle to introduction, our analysis 
of hospital admissions suggests that the benefits of 
vaccination would greatly outweigh the risks. Our 
benefit–risk estimates with age restrictions (1000:1) are 
consistent with a ratio of 841:1 estimated by Desai and 
colleagues, in 14 Latin American countries.42 It will be 
important to continue to monitor the benefits and 
risks of rotavirus vaccination as more post-licensure 
surveillance data emerge, particularly from MICs with a 
similar epidemiological profile to the countries included 
in our analysis.
This analysis has several limitations. We did not 
consider indirect (herd immunity) benefits of rotavirus 
vaccination. Post-licensure data from LMICs have 
provided mixed evidence on the scale of these possible 
effects.14 Therefore, our results are probably conservative 
because they might not capture the full extent of 
benefits from rotavirus vaccines. We assumed that 
most model parameters related to efficacy and 
intussusception were the same for all three vaccines 
due to no head-to-head data on these factors. If subtle 
or important differences in the effect, safety, or both of 
the products emerge from post-licensure studies, these 
differences will need to be considered when comparing 
products. We did not undertake a head-to-head com-
parison of the three products because of a scarcity of 
product-specific data that would fully account for 
differences in product characteristics and their impact 
Figure: Cost-effectiveness acceptability curves for the dominant vaccine (Rotasiil) compared with no vaccination
GDP=gross domestic product.



























Willingness-to-pay threshold (GDP per capita)
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on cost. For example, data on the cost of delivery and 
international transportation remain scarce and did 
not allow differentiation between products. However, 
one can reasonably assume that a product with a larger 
volume per dose might lead to higher transportation 
costs and potentially higher costs of delivery because of 
the larger cold chain space required for storage and 
transportation. More data are needed to account fully 


























All 63 MICs 3 022 783 4 475 501 1 452 717 2892 6687 3795 1045 669 383
Africa region 125 956 199 652 73 696 93 193 100 1357 1035 737
Algeria 33 837 98 579 64 742 25 100 76 1378 985 857
Botswana* 5818 6760 942 3 4 1 2098 1862 1100
Cabo Verde 1524 1752 228 1 1 0 2770 2471 1436
Equatorial Guinea 1327 1466 140 1 1 0 1733 1417 517
Gabon 4467 5156 689 2 3 1 2356 1877 810
Mauritius* 1724 1979 256 0 1 0 3568 2903 1286
Namibia* 5320 5355 35 2 2 0 2712 2643 548
South Africa* 68 535 75 199 6664 59 81 22 1159 926 302
Eswatini* 3404 3405 1 1 1 0 4828 4828 2834
Americas region 727 106 841 785 114 679 390 541 150 1862 1557 764
Argentina* 70 802 80 813 10 011 26 32 7 2769 2514 1522
Belize 769 936 168 0 0 0 2597 2285 1475
Brazil* 267 410 305 654 38 244 21 26 5 12 562 11 582 7495
Colombia* 65 831 75 356 9525 33 42 9 1989 1806 1102
Costa Rica* 9979 10 300 321 2 2 0 5756 5627 3320
Dominican Republic* 19 417 22 178 2761 10 13 3 1905 1728 1047
Ecuador* 24 965 28 687 3722 14 18 4 1778 1608 979
El Salvador* 12 365 12 529 164 5 5 0 2502 2502 2441
Grenada 214 243 29 0 0 0 3185 2747 1368
Guatemala* 21 713 27 781 6068 19 27 8 1132 1029 777
Jamaica 4537 5179 642 2 2 1 2651 2273 1131
Mexico* 134 045 165 614 31 569 203 303 100 661 546 314
Panama* 8954 10 173 1219 3 3 1 3579 3257 1961
Paraguay* 7541 8879 1337 6 8 2 1195 1113 803
Peru* 30 355 33 427 3073 20 22 2 1510 1509 1501
Saint Lucia 141 161 20 0 0 0 1464 1327 805
Saint Vincent and the 
Grenadines
104 119 15 0 0 0 1442 1305 794
Suriname 553 962 409 0 1 0 2141 1560 1141
Venezuela* 47 412 52 794 5381 26 36 10 1819 1483 564
Eastern Mediterranean 
region
720 361 796 815 76 454 704 865 161 1023 922 476
Egypt 281 721 286 688 4967 196 202 6 1439 1420 810
Iran 195 956 225 669 29 713 171 218 47 1147 1034 628
Iraq* 79 537 90 621 11 084 138 173 35 575 523 318
Jordan* 14 057 28 286 14 229 17 48 31 806 583 458
Lebanon 14 520 16 300 1780 12 15 3 1163 1054 595
Libya* 8279 9679 1400 15 18 4 571 523 352
Morocco* 56 221 64 536 8316 75 98 23 749 660 366
Palestine* 19 106 19 248 143 22 23 0 857 855 606
Syria 28 766 31 970 3204 37 46 9 775 694 359
Tunisia 22 198 23 817 1619 20 22 2 1101 1061 708
(Table 3 continues on next page)
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for the cost implications of different product 
characteristics, and only a few studies provide such 
comparisons.43 We included indirect costs as a measure 
of loss of income for caregivers in the societal 
perspective. Although this has the potential to overstate 
societal health-care costs, we explored wide ranges 
for this parameter in the probabilistic analysis 
(–50% to +50% of base input). Although our analysis 
assumed a small increased risk of intussusception with 
all three vaccines, we should note that studies in the 
past few years of Rotarix and Rotavac in low-income 
settings have reported no elevated risk,40,41 thus our 
benefit–risk ratio might be conservative.
As a multi-country analysis, results might differ 
slightly from country-focused analyses drawing on 
specific local data. Countries should interpret the results 
with caution and are encouraged to develop their own 
country-specific studies. Similarly, the vaccine prices in 
this analysis were estimates, so countries will need to 
confirm vaccine prices directly with manufacturers of 
products of interest. The results of this study should not 
dictate product choice decisions in a particular country, 
but they can inform pricing discussions. In some cases, 
in which third-party funding has been provided to a 
manufacturer to offset the cost of vaccine development, 
existing agreements related to that funding can provide 
countries access to better prices than they might be able 
to negotiate individually. In the regions of the Americas, 
the Pan American Health Organization Revolving 
Fund has successfully negotiated lower prices with 
manufacturers through pooled procurement for a 
group of countries. This kind of pooled procurement 
mechanism does not exist in many regions in which 
MICs are found.


























(Continued from previous page)
Europe region 299 645 464 244 164 600 193 327 134 1553 1419 1226
Albania* 2599 2991 392 2 2 0 1398 1307 912
Belarus 6066 12 876 6811 2 6 3 2732 2292 2005
Bosnia and Herzegovina 1938 2847 909 1 1 0 3017 2542 1903
Bulgaria* 6932 7921 989 3 4 1 2032 1878 1229
Croatia 2509 2857 348 2 3 0 1197 1118 758
Kazakhstan 23 793 32 480 8686 17 27 11 1418 1188 824
Kosovo 624 738 114 1 1 0 629 604 497
Montenegro 472 580 108 0 1 0 1117 1022 745
Romania 22 702 26 273 3571 11 13 2 2132 2038 1591
Russia 110 965 233 854 122 889 63 156 93 1775 1504 1321
Serbia 5500 6604 1105 5 6 1 1127 1043 761
North Macedonia* 1178 2674 1497 1 2 1 1648 1356 1189
Turkey 108 855 125 114 16 259 79 96 18 1387 1297 904
Turkmenistan* 5513 6434 921 7 9 2 756 711 523
Southeast Asia region 112 655 128 943 16 288 46 57 11 2470 2279 1486
Maldives 822 944 122 1 1 0 1373 1211 674
Thailand* 111 833 127 999 16 167 45 56 11 2485 2294 1499
Western Pacific region 1 037 062 2 044 061 1 007 000 1466 4705 3239 707 434 311
China 873 014 1 856 187 983 173 1337 4530 3194 653 410 308
Fiji* 1877 2127 250 1 2 0 1371 1146 513
Malaysia 67 013 76 718 9704 11 15 4 5990 5137 2589
Micronesia* 160 182 23 0 0 0 615 582 424
Philippines 94 124 107 866 13 743 115 156 40 816 693 341
Samoa 240 264 24 0 0 0 1174 1013 432
Tonga 189 212 23 0 0 0 1100 929 410
Tuvalu 18 20 2 0 0 0 807 697 343
Vanuatu 428 485 57 1 1 0 624 537 262
Data are estimates. Results shown for three-dose vaccines. MIC=middle-income country. RVGE=rotavirus gastroenteritis. *Countries using rotavirus vaccine as part of their 
national immunisation programme, as of July 9, 2020.7,10
Table 3: Risk–benefit of age-restricted and unrestricted schedules of vaccination for the period 2020–29
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On the basis of research on cost-effectiveness 
thresholds in the past decade,32,33 we elected to use the 
relatively stringent threshold of 0·5 GDP per capita in 
this study. Individual countries should interpret our 
results in light of their own benchmarks and policies. 
Additionally, decisions on rotavirus vaccine introduction 
and product selection should involve careful weighing of 
costs against various other considerations (eg, cold chain 
capacity, transport systems, and non-economic factors 
such as local epidemiology, ease of use, feasibility, and 
acceptability).
Many MICs have not yet introduced rotavirus vaccines, 
at least partly due to concerns about cost and cost-
effectiveness in the absence of international vaccine 
support. However, recent developments in product 
availability and market prices have improved the 
accessibility and value for money of rotavirus vaccines. 
This analysis provides strong evidence for the cost-
effectiveness and public health benefits of rotavirus 
vaccines in most MICs not eligible for funding from 
Gavi. Use of rotavirus vaccines in these countries has a 
high probability to be both beneficial and cost-effective 
if introduced in routine immunisation. In countries 
already implementing rotavirus vaccination, more 
recently prequalified products might be considered 
because they typically improve affordability and value for 
money.
Contributors
FD, AC, and CP designed the analysis, collected the data, ran the 
analysis, and interpreted the results. AC developed the model. JT, RB, 
CS, UP, and DA provided technical inputs to the study and contributed 
data. FD developed all tables and figures and wrote the initial draft of the 
manuscript. All coauthors reviewed and edited the final manuscript. 
All authors had access to all the data during the course of the study and 
FD, AC, and CP have verified the underlying data.
Declaration of interests
FD and RB report grants from the Bill & Melinda Gates Foundation 
during the course of the study. All other authors declare no competing 
interests.
Data sharing
All data used in this study are available either in the manuscript, in 
publications referenced in the study, or through the model that is available 
online.
Acknowledgments
The study was funded by a grant from the Bill & Melinda Gates 
Foundation (INV-007381 / OPP1147721 to Clint Pecenka). The findings 
and conclusions in this report are those of the author(s) and do not 
necessarily represent the official position of the US Centers for Disease 
Control and Prevention.
Editorial note: the Lancet Group takes a neutral position with respect to 
territorial claims in published maps and institutional affiliations.
References
1 Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and 
injuries in 204 countries and territories, 1990–2019: a systematic 
analysis for the Global Burden of Disease Study 2019. Lancet 2020; 
396: 1204–22.
2 Aballéa S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M. 
A critical literature review of health economic evaluations of 
rotavirus vaccination. Hum Vaccin Immunother 2013; 9: 1272–88.
3 Rheingans R, Amaya M, Anderson JD, Chakraborty P, Atem J. 
Systematic review of the economic value of diarrheal vaccines. 
Hum Vaccin Immunother 2014; 10: 1582–94.
4 Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, 
Islam MA, Thakkinstian A. Systematic review and meta-analysis of 
cost-effectiveness of rotavirus vaccine in low-income and lower-
middle-income countries. Open Forum Infect Dis 2019; 6: ofz117.
5 Kotirum S, Vutipongsatorn N, Kongpakwattana K, Hutubessy R, 
Chaiyakunapruk N. Global economic evaluations of rotavirus 
vaccines: a systematic review. Vaccine 2017; 35: 3364–86.
6 Debellut F, Clark A, Pecenka C, et al. Re-evaluating the potential 
impact and cost-effectiveness of rotavirus vaccination in 73 Gavi 
countries: a modelling study. Lancet Glob Health 2019; 7: e1664–74.
7 WHO Immunization, Vaccines and Biologicals. Vaccines in 
National Immunization Program. 2020. Available from 
https://www.who.int/immunization/monitoring_surveillance/
VaccineIntroStatus.pptx?ua=1 (accessed July 14, 2020).
8 Berkley S. Vaccination lags behind in middle-income countries. 
Nature 2019; 569: 309.
9 Mihigo R, Okeibunor J, Cernuschi T, Petu A, Satoulou A, Zawaira F. 
Improving access to affordable vaccines for middle-income 
countries in the african region. Vaccine 2019; 37: 2838–42.
10 International Vaccine Access Center. Johns Hopkins Bloomberg 
School of Public Health. VIEW-hub report: global vaccine 
introduction and implementation. 2020. https://view-hub.org/ 
(accessed July 14, 2020).
11 Aliabadi N, Tate JE, Parashar UD. Potential safety issues and other 
factors that may affect the introduction and uptake of rotavirus 
vaccines. Clin Microbiol Infect 2016; 22 (suppl 5): S128–35.
12 Apte A, Roy S, Bavdekar A, Juvekar S, Hirve S. Facilitators and 
barriers for use of rotavirus vaccine amongst various stakeholders 
and its implications for Indian context—a systematic review. 
Hum Vaccin Immunother 2018; 14: 2760–67.
13 WHO. Rotavirus vaccines WHO position paper—January 2013. 
Wkly Epidemiol Rec 2013; 88: 49–64.
14 Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and 
intussusception risks of rotavirus vaccination in 135 low-income 
and middle-income countries: a modelling analysis of current and 
alternative schedules. Lancet Glob Health 2019; 7: e1541–52.
15 Arlegui H, Nachbaur G, Praet N, Bégaud B. Quantitative benefit-
risk models used for rotavirus vaccination: a systematic review. 
Open Forum Infect Dis 2020; 7: a087.
16 WHO. WHO prequalified vaccines. https://www.who.int/
immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/ 
(accessed July 14, 2020).
17 Anwari P, Debellut F, Pecenka C, et al. Potential impact and cost-
effectiveness of rotavirus vaccination in Afghanistan. Vaccine 2018; 
36: 7769–74.
18 Lusvan ME, Debellut F, Clark A, et al. Projected impact, cost-
effectiveness, and budget implications of rotavirus vaccination in 
Mongolia. Vaccine 2019; 37: 798–807.
19 Lee H, Park SY, Clark A, et al. Cost-effectiveness analysis of the 
implementation of a National Immunization Program for rotavirus 
vaccination in a country with a low rotavirus gastroenteritis-related 
mortality: a South Korean study. Vaccine 2019; 37: 4987–95.
20 Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, 
Chinnakali P. Impact and cost effectiveness of pneumococcal 
conjugate vaccine in India. Vaccine 2019; 37: 623–30.
21 Anwari P, Debellut F, Vodicka E, et al. Potential health impact and 
cost-effectiveness of bivalent human papillomavirus (HPV) 
vaccination in Afghanistan. Vaccine 2020; 38: 1352–62.
22 Hasso-Agopsowicz M, Ladva CN, Lopman B, et al. Global review of 
the age distribution of rotavirus disease in children aged <5 years 
before the introduction of rotavirus vaccination Clin Infect Dis 2019; 
69: 1071–78.
23 Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the 
Global Burden of Disease 2013 study. Lancet Glob Health 2015; 
3: e712–23.
24 WHO. WHO-UNICEF estimates of immunization coverage. 
https://www.who.int/immunization/monitoring_surveillance/
routine/coverage/en/index4.html (accessed July 14, 2020).
25 Clark A, Sanderson C. Timing of children’s vaccinations in 45 low-
income and middle-income countries: an analysis of survey data. 
Lancet 2009; 373: 1543–49.
26 Clark A, van Zandvoort K, Flasche S, et al. Efficacy of live oral 
rotavirus vaccines by duration of follow-up: a meta-regression of 
randomised controlled trials. Lancet Infect Dis 2019; 19: 717–27.




www.thelancet.com/lancetgh   Vol 9   July 2021 e956
27 Rogawski ET, Platts-Mills JA, Ross Colgate E, et al. Quantifying the 
impact of natural immunity on rotavirus vaccine efficacy estimates: 
a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation 
study. J Infect Dis Nat Immun Vaccine Effic 2018; 861: 861–68.
28 Baral R, Nonvignon J, Debellut F, Agyemang SA, Clark A, 
Pecenka C. Cost of illness for childhood diarrhea in low- and 
middle-income countries: a systematic review of evidence and 
modelled estimates. BMC Public Health 2020; 20: 619.
29 Doucleff M. Merck pulls out of agreement to supply life-saving 
rotavirus vaccine to millions of kids. NPR. 2018. https://www.npr.
org/sections/goatsandsoda/2018/11/01/655844287/merck-pulls-out-
of-agreement-to-supply-life-saving-vaccine-to-millions-of-kids 
(accessed July 14, 2020).
30 Vaccine R. Supply and demand update UNICEF supply division. 
2020. https://www.unicef.org/supply/media/2351/file/
Rotavirus%20vaccine%20supply%20and%20demand%20update.
pdf (accessed July 14, 2020).
31 Immunization Costing Action Network. Immunization delivery cost 
catalogue. 2019. https://immunizationeconomics.org/ican-idcc 
(accessed April 3, 2020).
32 Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-
effectiveness thresholds: initial estimates and the need for further 
research. Value Health 2016; 19: 929–35.
33 Ochalek J, Lomas J, Claxton K. Research paper 122 cost per DALY 
averted thresholds for low-and middle-income countries: evidence 
from cross country data. Centre for Health Economics. 2015. 
http://www.york.ac.uk/media/che/documents/papers/
researchpapers/CHERP122_cost_DALY_LMIC_threshold.pdf 
(accessed July 14, 2020).
34 NICE International, Bill and Melinda Gates Foundation. Methods 




35 Brenzel L. Common approach for the costing and financing 
analyses of routine immunization and new vaccine introduction 




36 Resch S, Menzies N, Portnoy A, et al. How to cost immunization 
programs: a practical guide on primary data collection and analysis. 
Cambridge, MA: Harvard T H Chan School of Public Health, 2020.
37 Clark AD, Hasso-Agopsowicz M, Kraus MW, et al. Update on the 
global epidemiology of intussusception: a systematic review of 
incidence rates, age distributions and case-fatality ratios among 
children aged <5 years, before the introduction of rotavirus 
vaccination Int J Epidemiol 2019; 48: 1316–26.
38 Pecenka C, Debellut F, Bar-Zeev N, Anwari P, Nonvignon J, 
Clark A. Cost-effectiveness analysis for rotavirus vaccine decision-
making: how can we best inform evolving and complex choices in 
vaccine product selection? Vaccine 2020; 38: 1277–79.
39 Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception 
among infants given an oral rotavirus vaccine. N Engl J Med 2001; 
344: 564–72.
40 Tate JE, Mwenda JM, Armah G, et al. Evaluation of intussusception 
after monovalent rotavirus vaccination in Africa. N Engl J Med 2018; 
378: 1521–28.
41 Reddy SN, Nair NP, Tate JE, et al. Intussusception after rotavirus 
vaccine introduction in India. N Engl J Med 2020; 383: 1932–40.
42 Desai R, Parashar UD, Lopman B, et al. Potential intussusception 
risk versus health benefits from rotavirus vaccination in Latin 
America. Clin Infect Dis 2012; 54: 1397–405.
43 Debellut F, Jaber S, Bouzya Y, et al. Introduction of rotavirus 
vaccination in Palestine: an evaluation of the costs, impact, and 
cost-effectiveness of ROTARIX and ROTAVAC. PLoS One 2020; 
15: e0228506.
